Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (1371)

« Back to Publications

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

Scanlon E. et al, (2024), Esmo open, 9

Microbiology testing capacity and antimicrobial drug resistance in surgical-site infections: a post-hoc, prospective, secondary analysis of the FALCON randomised trial in seven low-income and middle-income countries.

NIHR Global Health Research Unit on Global Surgery None., (2024), Lancet glob health

Risk Stratification in Older Intensively Treated Patients With AML.

Versluis J. et al, (2024), J clin oncol

Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event

Tackney MS. et al, (2024), Trials, 25

Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project

Black J. et al, (2024), Trials

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial.

Worth C. et al, (2024), Lancet rheumatol

Statistical analysis plan for the TRANSLATE (TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation of potentially clinically significant prostate cancer) multicentre randomised controlled trial.

Marian IR. et al, (2024), Trials, 25

A proposal for using benefit-risk methods to improve the prominence of adverse event results when reporting trials

Totton N. et al, (2024), Trials

Reports of randomised control trials should begin and conclude with up-to-date systematic reviews of other relevant trials: a 25-year audit of the quality of trial reports.

Clarke M. et al, (2024), J r soc med, 117, 212 - 216

Mobility and strength training with and without protein supplements for pre-frail or frail older adults with low protein intake: the Maximising Mobility and Strength Training (MMoST) feasibility randomised controlled trial protocol

Biggin K. et al, (2024), Nihr open research, 3, 62 - 62

Current usage of explainer animations in trials: a survey of the UKCRC registered clinical trial units in the UK.

Barber VS. et al, (2024), Trials, 25

Pharmacological interventions for early-stage frozen shoulder: a systematic review and network meta-analysis.

Berner JE. et al, (2024), Rheumatology (oxford)

Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project

Black J. et al, (2024)

Response to Letter from Wong on determining the target difference in sample size calculations for randomised controlled trials.

Cook JA. and Parker RA., (2024), Trials, 25

Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements.

Tunn R. et al, (2024), J clin epidemiol

Radiological outcomes following surgical fixation with wires versus moulded cast for patients with a dorsally displaced fracture of the distal radius: a radiographic analysis from the DRAFFT2 trial.

Plant CE. et al, (2024), Bone jt open, 5, 132 - 138

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

Abhishek A. et al, (2024), Lancet rheumatol, 6, e92 - e104

Enhancing Regulatory Compliance in Research Electronic Data Capture (REDCap): the MHRAFix external module (Preprint)

Appelbe DE. et al, (2024)

Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.

Murray SM. et al, (2024), J hepatol, 80, 109 - 123

Robust generation of neutralising antibodies against Omicron variants following bivalent mRNA booster vaccine in elderly people aged >80 years.

Parry H. et al, (2024), J infect, 88, 48 - 50

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?